Products with Anti-diabetic complications bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN3787 | Nothofagin |
| 1. Nothofagin has antioxidant activity. 2. Nothofagin and Aspalathin may have significant benefits in the treatment of diabetic complications. 3. Nothofagin and Aspalathin possess antithrombotic activity and offers a basis for development of a novel anticoagulant. 4. Nothofagin and Aspalathin possess anti-inflammatory activity by inhibiting hyperpermeability, expression of CAMs, and adhesion and migration of leukocytes, thereby endorsing its usefulness as a therapy for vascular inflammatory diseases. 5. Nothofagin and Aspalathin have potential to as an anti-sendothelial cell protein C receptor shedding reagent against phorbol-12-myristate 13-acetate and cecal ligation and puncture -mediated endothelial cell protein C receptor shedding. | |
| BCN3869 | Alliin |
| 1. Alliin protects against Lipopolysaccharides (LPS)-induced acute lung injury (ALI) by activating PPARγ, which subsequently inhibits LPS-induced NF-κB activation and inflammatory response, alliin may be used as an anti-inflammatory agent in the treatment of ALI. 2. Alliin has antiglycating potential , it offers protection against glucose or methyglyoxal induced glycation of superoxide dismutase. 3. Alliin has a good antiglycating effect and hence is expected to have therapeutic potential in the prevention of glycation-mediated diabetic complications. 4. Alliin and sabinene have detectable levels of antimicrobial activity. 5. Alliin has an inhibitory effect in osteoclasteogenesis with a dose-dependent manner via blocking the c-Fos-NFATc1 signaling pathway, it could be a potential therapeutic agent in the treatment of osteoporosis. | |
| BCN5122 | Isoferulic acid |
| Isoferulic acid is an effective natural antioxidant in both lipid and aqueous media, it may be a new promising anti-glycation agent for the prevention of diabetic complications via inhibition of advanced glycation end products (AGEs) formation and oxidation-dependent protein damage. Isoferulic acid is a novel and potent inhibitor of murine IL-8 production, it also has inhibitory effect on mushroom tyrosinase.3-Hydroxy-4-methoxycinnamic acid shows anti-inflammatory, antiviral, antioxidant, and antidiabetic properties, it is an anti-glycation agent, inhibits fructose- and glucose-mediated protein glycation. | |
| BCN5291 | Ziyuglycoside II |
| Ziyuglycoside II has a wide range of clinical applications including hemostasis, antibiosis, anti-inflammation and anti-oxidation. Ziyuglycoside II has inhibitory effect on the growth of MDA-MB-435 cells, it induces cell cycle arrest and apoptosis through activation of ROS/JNK pathway in human breast cancer cells.Ziyuglycoside II methyl ester possess improved anti-diabetic properties, and has hepato-renal protective activities in type 2 diabetes. | |
| BCN5355 | Aucubin |
| Aucubin is an iridoid glycoside with a wide range of biological activities, including pancreas-protective, chondroprotective, antispasmodic, liver-protective, anti-inflammatory, anti-microbial, antioxidant, anti-algesic as well as anti-tumor activities. Aucubin prevents neuronal death in the hippocampal CA1 region in rats with diabetic encephalopathy, it also has protective effects on H2O2-induced apoptosis in PC12 cells. Aucubin may improve obesity-induced atherosclerosis by attenuating TNF-α-induced inflammatory responses. Aucubin suppresses hepatitis B viral DNA replication in vitro. | |
